Single-Port Platform Advances Minimally Invasive Surgery

The design closely mimics traditional laparoscopic equipment, so that the surgeon feels as if he is operating two different tools, each in their own trocar, in a more ergonomic fashion and with fewer complications. Additional benefits include lower usage of analgesics and fewer readmissions for hernias and incision-site infections.

The symphonX Surgical Platform is compatible with a standard 15 mm laparoscopic trocar. The first commercial procedure, with symphonX in the United States a gallbladder extraction, was performed by Professor Santiago Horgan, MD, chief of minimally invasive surgery at UC San Diego Health (UCSD; CA, USA). The symphonX Surgical Platform is a product of Fortimedix Surgical (Nuth, The Netherlands), and has been approved by the U.S. Food and Drug Administration (FDA).

“We are thrilled to formally launch the symphonX Surgical Platform in the United States, which we believe has the potential to deliver on the promise of single-port surgery and elevate the standard of care in laparoscopy,” said Tom Dempsey, VP Sales of Fortimedix Surgical. “Our early clinical experience underlines its potential for improved patient satisfaction and health outcomes, including fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis.”

Single-port laparoscopic surgery is used to perform many types of surgery, including adjustable gastric banding, appendectomy, cholecystectomy, hernia repair, hysterectomy, and others. When compared with traditional multi-port laparoscopic techniques, benefits include less postoperative pain, less blood loss, faster recovery time, and better cosmetic results. Despite the potential advantages, there may also be complications, including significant postoperative pain, injury to organs, bleeding, infection, incisional hernia, intestinal adhesions, and scarring.

Related Links:
Fortimedix Surgical